ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).
| Autor: | Laccetti, Andrew Leonard, Smith, Matthew Raymond, Scher, Howard I., Verholen, Frank, Adorjan, Patrick, Dissanayake, Manjari, Gao, Xin |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS243-TPS243, 235p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|